Influenza is an infection of the throat, nose and lungs. It is commonly referred as flu, but its complications can be deadly. At first, it seems like common cold with sore throat, runny nose and sneezing. Cold usually develops slowly then it tends to come suddenly, including symptoms such as fever, headache, shortages of breath, chills and sweats. It spread mainly by tiny droplets of flu cough, sneeze or talk. These droplets can land in mouth or noses of nearby person and might get flu by touching a surface or object that has virus on it. Although, influenza vaccine isn't as much effective but it reduces the chances of having severe complications from infection.
The U.S. influenza vaccines market is estimated to be valued at US$ 3,975.7 million in 2022 and is expected to exhibit a CAGR of 16.3% during the forecast period (2022-2030).
Figure 1. U.S. Influenza Vaccines Market Share (%), by Vaccine Type, 2022
U.S. Influenza Vaccines Market - Driver
Increasing inorganic strategies such as product approval from regulatory authorities such as the U.S. Food and Drug Administration is expected to boost the growth of the U.S. influenza vaccines market. For instance, in February 2021, Seqirus USA Inc., a pharmaceutical company, announced that they had received approval from the U.S. Food and Drug Administration for Fluad Quadrivalent, the first adjuvanted quadrivalent influenza vaccine adults 65 years and older against. This vaccine will strengthen and broaden the body’s immune response against the influenza.
|Base Year:||2021||Market Size in 2022:||US$ 3,975.7 Mn|
|Historical Data for:||2017 to 2020||Forecast Period:||2022 to 2030|
|Forecast Period 2022 to 2030 CAGR:||16.3 %||2030 Value Projection:||US$ 13,310.2 Mn|
Seqirus USA Inc., GSK plc., Sanofi, Pfizer Inc., AstraZeneca, Novartis AG, Merck & Co., Inc., Protein Sciences Corporation, Moderna, Inc., INOVIO Pharmaceuticals, Novavax and EMERGENT
|Restraints & Challenges:||
Figure 2. U.S. Influenza Vaccines Market Share (%), by Virus Type, 2022
U.S. Influenza Vaccines Market– Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.
COVID-19 can affect the economy in three main ways: by directly affecting production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, U.A.E., Egypt, and others, are facing problems with regards to the transportation of drugs from one place to another.
However, the COVID-19 pandemic had a positive impact on the U.S. influenza vaccines market due to the increasing influenza vaccinations during COVID-19. For instance, according to the data published in December 2021, by Centers for Disease Control and Prevention, flu vaccinations has increased by 9% during the last quarter of 2020. Vaccinations of adults from 18 to 64 years rose by 15% while of adolescents increased by 13% in U.S. Influenza vaccinations among all age group help to reduce the respiratory illness and protect essential workers from the flu, and conserve medical resources for patients with COVID-19.
U.S. Influenza Vaccines Market: Key Developments
Adoption of inorganic growth strategies such as product approval from regulatory authorities such as U.S. Food and Drug Administration is expected to drive the U.S. influenza vaccines market. For instance, in October 2021, Seqirus USA Inc., a pharmaceutical company, announced that they had received an approval from U.S. Food and Drugs Administration for Quadrivalent influenza vaccine for children of six months and older. Quadrivalent influenza vaccine is the first cell-based influenza vaccine in the U.S. which may have the potential for greater vaccine effectiveness.
U.S. Influenza Vaccines Market: Restraint
Shortages of vaccines supply in the U.S. is expected to hamper the growth of the U.S. influenza vaccines market over the forecast period. For instance, in October 2020, according to the data published by the Center for Infectious Disease Research and Policy (CIDRAP), flu vaccines was low or out of stock in the U.S. The vaccine shortages was due to manufacturing or production problems, insufficient stockpiles.
U.S. Influenza Vaccines Market - Key Players
Major players operating in the U.S. influenza vaccines market include Seqirus USA Inc., GSK plc., Sanofi, Pfizer Inc., AstraZeneca, Novartis AG, Merck & Co., Inc., Protein Sciences Corporation, Moderna, Inc., INOVIO Pharmaceuticals, Novavax and EMERGENT
Influenza is commonly referred as flu, a contagious respiratory illness which is caused by influenza virus. The virus can cause mild to severe illness, resulting in serious outcomes such as hospitalization or death. Geriatric population, pregnant women, and people with chronic health conditions are at high risk of serious flu complications. Influenza virus is responsible for seasonal epidemic events and are classified into two types of influenza virus, including A and B. Seasonal influenza is characterized by a sudden onset of fever, cough, headache, muscle and joint pain, sore throat and a runny nose. The cough can be severe and can last 2 or more weeks. Vaccination for influenza aids in prevention of flu. This vaccine is recommended for children aged 6 months and older. Influenza virus is transmitted primarily by respiratory secretions or droplets of the infected person. Influenza (influenza A and influenza B) epidemics occur seasonally and vary in severity each year by causing respiratory illnesses and placing a substantial burden on healthcare systems.
Increasing research and development of influenza vaccines by key market players is expected to drive the U.S. influenza vaccines market over the forecast period. For instance, in June 2022, Moderna, Inc., a biotechnology company, announced that they had started patient dosing in phase 3 study of seasonal influenza vaccine candidate, MRNA-1010 which is the first of several influenza vaccine candidates developed for improving traditional vaccines by inducing broad and robust immune responses. MRNA-1010 is a vaccine candidate that encodes for hemagglutinin glycoproteins for the four influenza strains for the prevention of influenza, including influenza A/H1N1, A/H3N2, and influenza B/Yamagata- and B/Victoria-lineages.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.